Keywords
How to Cite
Abstract
Objectives: to study the long-term results of surgical treatment of patients with medullary thyroid carcinoma and evaluate the significance of prognostic factors.
Materials and methods: the continuous retrospective study included 169 patients with histologically confirmed medullary cancer who were initially operated at the Northwestern Center for Endocrinology and Endocrine Surgery of the SPbSU University Clinic from 2010 to 2016. They were divided into prognostic groups according to the level and dynamics of postoperative calcitonin and clinical manifestations of the disease.
Results: The study allowed to assess the effect of predictive factors on the risks of progression and recurrence in medullary thyroid cancer.
Size of the primary tumor more than 2 cm significantly increases the risk of disease progression (OR=6,56 (0.52-17.96) p=0,00001495). Invasion of the thyroid capsule and metastases to regional lymph nodes are even more important prognostic value as OR=49,08 (10.72-224.89), p=0,00000011 и OR=30,63 (9,75-96,27), p<0.0000001 respectively.
Regional MTC metastases are a significant threat to the life of the patient. This fact is a fundamental difference with differentiated thyroid carcinoma were regional metastases do not affect the prognosis.
This study failed to link the prognosis to the patient's age.
As expected the level of basal calcitonin >600 pg/ml affects the prognosis (OR=6,65 (2,53-17,59) p=0.01055). Its prognostic value is comparable to the size of the primary tumor and significantly less than the presence of regional and distant metastases.
Conclusions: Unfavorable prognosis in 21 (12.4%) observed patients is associated not only with the presence of distant metastases, but also and independently with regional ones.
References
Kebebew E., Ituarte P.H.G., Siperstein A.E. et al. Medullary thyroid carcinoma. Cancer. 2000; 88: 1139-1148. https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z.
Lim H., Devesa S.S., Sosa J.A. et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–1348. https://doi.org/10.1001/jama.2017.2719.
Oh C.M., Jung K.W., Won Y.J. et al. Age-period-cohort analysis of thyroid cancer incidence in Korea. Cancer Research and Treatment. 2015;47(3):362–369. https://doi.org/10.4143/crt.2014.110.
Hazard J.B., Hawk W.A., Crile G. Medullary (solid) carcinoma of the thyroid—a clinicopathologic entity. The Journal of Clinical Endocrinology & Metabolism. 1959;19(Issue 1):152-161. https://doi.org/10.1210/jcem-19-1-152.
Randle R.W., Balentine C.J., Leverson G.E. et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017; 161(1): 137-146. https://doi.org/10.1016/j.surg.2016.04.053.
Elisei R., Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol. 2012;8:466–475. https://doi.org/10.1038/nrendo.2012.38.
Wells S.A., Asa S.L., Dralle H. et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 2015;25(6): 567-610. https://doi.org/10.1089/thy.2014.0335.
Lodish M.B., Stratakis C.A. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer, Expert Review of Anticancer Therapy. 2008; 8(4): 625-632. https://doi.org/10.1586/14737140.8.4.625.
Elisei R., Cosci B., Romei C. et al. Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study. The Journal of Clinical Endocrinology & Metabolism. 2008; 93(3): 682-687. https://doi.org/10.1210/jc.2007-1714.
Сiampi R., Romei C., Ramone T. et al. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. iScience. 2019 Oct 25;20:324-336. doi: 10.1016/j.isci.2019.09.030.
Meijer J.A.A., le Cessie S., van den Hout W.B. et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clinical Endocrinology. 2010; 72(4):534–542. doi:10.1111/j.1365-2265.2009.03666.x.
Hyer S.L., Vini L., A’Hern R. et al. Medullary thyroid cancer: Multivariate analysis of prognostic factors influencing survival. European Journal of Surgical Oncology. 2000; 26(7):686–690. https://doi.org/10.1053/ejso.2000.0981.
Kuo E.J., Sho S., Li N. et al. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surgery. 2018; 153(1): 52–59. https://doi.org/10.1001/jamasurg.2017.3555.
De Groot J.W.B., Plukker J.T.M., Wolffenbuttel B.H.R. et al. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clinical Endocrinology. 2006; 65: 729-736. doi:10.1111/j.1365-2265.2006.02659.x.
Черников Р.А., Валдина Е.А., Воробьев С.Л., Слепцов И.В., Семенов А.А., Чинчук И.К., и др. Отдаленные результаты хирургического лечения при папиллярном раке щитовидной железы и сравнительная оценка тактики лечения. Клиническая и экспериментальная тиреоидология. 2014;10(1):31-37. https://doi.org/10.14341/CET201410131-37.
Roman S., Lin R., Sosa J.A. Prognosis of medullary thyroid carcinoma. Cancer. 2006; 107: 2134-2142. doi:10.1002/cncr.22244.
Медведев В.С., Исаев П.А., Ильин А.А. и др. Медуллярная карцинома щитовидной железы. Опухоли головы и шеи. 2013;(2):31-36. https://doi.org/10.17650/2222-1468-2013-0-2-31-36 [Medvedev V.S., Isayev P.A., Ilyin A.A. et al. Medullary thyroid carcinoma. Head and Neck Tumors 2013 2013;(2):31-36 (In Russ.)].
Румянцев П.О., Ильин А.А., Румянцева У.В. и др. Факторы клинического прогноза медуллярного рака щитовидной железы. Опухоли головы и шеи. 2011; 4: 48-54 [Rumyantsev P.O., Ilyin A.A., Rumyantseva U.V. et al. Clinical prognostic factors in medullary thyroid carcinoma. Head and Neck Tumors 2011; 4; 48-54 (In Russ.)].
Макарьин В.А., Успенская А.А., Семенов А.А., и др. Потеря сигнала (loss of signal) при интраоперационном нейромониторинге гортанных нервов как предиктор послеоперационного пареза гортани: анализ 1065 последовательных операций на щитовидной и околощитовидных железах. Тактика хирурга. Эндокринная хирургия, 10(3), 15-24. doi:10.14341/serg2016315-24 [Makarin V., Uspenskaya A., Semenov A. et al. Loss of signal during intraoperative neuromonitoring of laryngeal nerves as a predictor of postoperative larynx paresis: Analysis of 1065 consequetive thyroid and parathyroid operations. Surgeons' algorythm (tactics). Endocrine Surgery. 2017 10(3), 15-24. doi: 10. 15. 10.14341/serg2016315-24 (In Russ.)].
Слепцов И.В., Бубнов А.Н., Черников Р.А. и др. Фотодинамическая визуализация околощитовидных железы – результаты клинического применения. Клиническая и экспериментальная тиреоидология. 2009;5(1):35-40. doi: 10.14341/ket20095135-40 [Slepzov I.V., Bubnov A.N., Chernikov R.A. et al. Photodynamic Vvisualisation of Paratyroid Glands – Results of Clinical use Eng. Clinical and experimental thyroidology. 2009;5(1):35-40. https://doi.org/10.14341/ket20095135-40 (In Russ.)].
Takami H., Ito Y., Noguchi H. et al. (eds.). Treatment of Thyroid Tumor: Japanese Clinical Guidelines. doi:10.1007/978-4-431-54049-6.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021